Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
Open Access
- 3 April 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 22 (6), 1191-1199
- https://doi.org/10.1038/leu.2008.74
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Flying under the radar: the new wave of BCR–ABL inhibitorsNature Reviews Drug Discovery, 2007
- Chronic myeloid leukaemia as a model of disease evolution in human cancerNature Reviews Cancer, 2007
- Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cellsHaematologica, 2007
- Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood, 2006
- Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinationsBlood, 2006
- Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanateCancer Cell, 2006
- Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemiaBlood, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001
- High-Performance Liquid Chromatography-Based Determination of Total Isothiocyanate Levels in Human Plasma: Application to Studies with 2-Phenethyl IsothiocyanateAnalytical Biochemistry, 2001
- The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic CellsOnline Journal of Public Health Informatics, 2000